At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 258 enrolled
Drug / intervention
phenazopyridine HCl +1 moredrug
Likely dose
phenazopyridine HCl 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
THE CAT(H) STUDY CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial A CREST 2010 Project
In Brief
A Phase 4 clinical trial evaluating phenazopyridine HCl and Placebo for Catheter-related Bladder Discomfort. Completed, enrolled 258 participants across 1 site.
Detailed Summary
The primary aim of this randomized clinical trial is to compare the utility of phenazopyridine HCl vs. placebo in reducing catheter-associated discomfort during the post-operative period in the gynecologic patient using mean VAS measurments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCatheter-related Bladder Discomfort
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedOct 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedOct 13, 2008
Enrollment StartAug 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.7 years ago
Interventions
phenazopyridine HCldrug
Phenazopyrdine HCl 200 mg q8h x 24
Placeboother
Placebo tablet administered q8 hours for 24 hours postop.